El objetivo de este reporte es determinar el nivel de respuesta humoral alcanzado tras la aplicación de la tercera dosis de refuerzo de BNT162b2 seguido de un régimen completo de BBIBP-CorV, evaluar los factores asociados a mayores anticuerpos IgG anti-SARS-CoV-2 y reportar los eventos adversos a la aplicación de este refuerzo mixto.

Background: The inactivated virus vaccine, BBIBP-CorV, was principally distributed across low- and middle-income countries as primary vaccination strategy to prevent poor COVID-19 outcomes. Limited information is available regarding its effect on heterologous boosting. We aim to evaluate the immunogenicity and reactogenicity of a third booster dose of BNT162b2 following a double BBIBP-CorV regime. Methods: We conducted a cross-sectional study among healthcare providers from several healthcare facilities of the Seguro Social de Salud del Perú - ESSALUD. We included participants two-dose BBIBPCorV vaccinated who presented a three-dose vaccination card at least 21 days passed since the vaccinees received their third dose and were willing to provide written informed consent. Antibodies were determined using LIAISON SARS-CoV-2 TrimericS IgG (DiaSorin Inc., Stillwater, USA). Factors potential...